14 Jun 2019 11:00
Â
ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES") | |||||||||||||||||||||||||||||||||
COMPANY NAME: | |||||||||||||||||||||||||||||||||
 Venn Life Sciences Holdings plc  | |||||||||||||||||||||||||||||||||
COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) : | |||||||||||||||||||||||||||||||||
 Registered Office:  PO Box W1J 6BD, Berkley Square House, 2nd Floor, Mayfair, London, W1J 8DJ  Trading Office:  19 Railway Road, Dalkey, Dublin, Ireland  | |||||||||||||||||||||||||||||||||
COUNTRY OF INCORPORATION: | |||||||||||||||||||||||||||||||||
 England and Wales  | |||||||||||||||||||||||||||||||||
COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26: | |||||||||||||||||||||||||||||||||
 www.vennlifesciences.com/ and with effect from Admission, www.openorphan.com  | |||||||||||||||||||||||||||||||||
COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: | |||||||||||||||||||||||||||||||||
 This is a reverse takeover under Rule 14.  Open Orphan is Clinical Research Organisation that specialises in rare and orphan drugs. The headquarters are in Dublin, Ireland and the company also has offices in France, the Netherlands and Germany.  | |||||||||||||||||||||||||||||||||
DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares): | |||||||||||||||||||||||||||||||||
 Number of ordinary shares of 0.1 pence each in nominal value ("Ordinary Shares") for which Admission will be sought: 253,493,259  Placing price per Ordinary Share: 5.6 pence  The are no restrictions as to the transferability of the Ordinary Shares and no Ordinary Shares will be held in treasury.  | |||||||||||||||||||||||||||||||||
CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: | |||||||||||||||||||||||||||||||||
 Capital to be raised on admission: £4.5 million  Anticipated market capitalisation on admission: £14.1 million  | |||||||||||||||||||||||||||||||||
PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: | |||||||||||||||||||||||||||||||||
 31.1%  | |||||||||||||||||||||||||||||||||
DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED: | |||||||||||||||||||||||||||||||||
 Euronext Growth  | |||||||||||||||||||||||||||||||||
FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known): | |||||||||||||||||||||||||||||||||
 Directors:  Brendan Buckley, Non-executive Chairman Cathal Friel, Chief Executive Officer Christian Milla, Chief Operating Officer Tony Richardson, Corporate Development Officer Michael Ryan, Senior non-executive Director  Proposed Director:  Maurice Treacy, Executive Director  | |||||||||||||||||||||||||||||||||
FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known): | |||||||||||||||||||||||||||||||||
 Before Admission Â
 After Admission Â
  | |||||||||||||||||||||||||||||||||
NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: | |||||||||||||||||||||||||||||||||
 n/a  | |||||||||||||||||||||||||||||||||
(i) ANTICIPATED ACCOUNTING REFERENCE DATE (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information) (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19: | |||||||||||||||||||||||||||||||||
 (i) 31 December (ii) 31 December 2018 (iii) 30 June 2019 due 30 September 2019, 31 December 2019 due 30 June 2020, 30 June 2020 due September 2020  | |||||||||||||||||||||||||||||||||
EXPECTED ADMISSION DATE: | |||||||||||||||||||||||||||||||||
 28 June 2019  | |||||||||||||||||||||||||||||||||
NAME AND ADDRESS OF NOMINATED ADVISER: | |||||||||||||||||||||||||||||||||
 Arden Partners plc 125 Old Broad Street London EC2N 1AR  | |||||||||||||||||||||||||||||||||
NAME AND ADDRESS OF BROKER: | |||||||||||||||||||||||||||||||||
 Arden Partners plc 125 Old Broad Street London EC2N 1AR   | |||||||||||||||||||||||||||||||||
OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: | |||||||||||||||||||||||||||||||||
A copy of the admission document containing full details about the applicant and the admission of its securities will be available on the Company's website, www.vennlifesciences.com  | |||||||||||||||||||||||||||||||||
THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY | |||||||||||||||||||||||||||||||||
 The QCA Corporate Governance Code 2018 published by the Quoted Companies Alliance  | |||||||||||||||||||||||||||||||||
DATE OF NOTIFICATION: | |||||||||||||||||||||||||||||||||
 14 June 2019  | |||||||||||||||||||||||||||||||||
NEW/ UPDATE: | |||||||||||||||||||||||||||||||||
 New  |
Â
Â
Â